Pharmaceuticals

Brawn Biotech Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.

10 of 25 filings·Updated 14 Aug 2026

14 Aug 20261 filing

Company UpdateNewspaper Publication

Publication of Un-audited financial results for the quarter ended June 30, 2026.

Filed 11:39View Source

13 Aug 20261 filing

ResultFinancial Results

Brawn Biotech approves unaudited Q1 June 30, 2026 results; appoints auditors; fixes AGM date.

Financial results

Board approved standalone unaudited quarterly results for quarter ended 30 June 2026.
Limited Review Report accompanying the results was approved.
Board meeting held on 13 August 2026.

Auditors

Recommend appointment of M/s GD S M and Co as statutory auditors for five years.
Term from AGM 2026-27 to AGM 2030-31, subject to shareholder approval.

AGM & notices

41st AGM via VC/OAVM on Sep 29, 2026.
Draft AGM notice to shareholders.

Board report & CFO certificate

Board approved the Board Report for year ended March 31, 2026.
CFO certificate under Reg 33(2)(a) confirms unaudited results as true and fair.

Filed 13:17View Source

5 Aug 20261 filing

Board Meeting

Board meeting details not disclosed in filing chunk for Brawn Biotech Ltd

No scheduled date, time, or location disclosed in the filing chunk.

Filed 16:57View Source

8 Jul 20261 filing

Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Regulation 74(5) certificate confirms dematerialisation processing and owner update; securities listed.

Dematerialisation status

Dematerialisation requests received were confirmed to depositories; securities listed on exchanges.
Dematerialisation certificates were mutilated and cancelled after due verification.
Depository's name substituted as registered owner within 15 days.

Filed 15:49View Source

29 May 20261 filing

Board MeetingOutcome of Board Meeting

Brawn Biotech Ltd - 530207 - Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held On 29Th May 2026, And Submissions Of Audited Financial Results For The Quarter And Year Ended 31.03.2026

Financial results approved

Approved audited standalone financial results for quarter and year ended 31 March 2026.
Statutory auditor issued an unmodified audit opinion on the standalone results.

Annual statements approved

Approved standalone balance sheet, profit and loss account, cash flow statement, and notes for FY2026.
Authorized Brij Raj Gupta to sign and submit the audited results to stock exchanges.

Key financial highlights

FY2026 standalone revenue from operations was Rs 1,697.77 lakh.
FY2026 standalone profit after tax was Rs 94.06 lakh.
FY2026 total comprehensive income was Rs 97.71 lakh.
Paid-up equity share capital remained Rs 300.03 lakh.

Governance and compliance

Board meeting held on 29 May 2026 and concluded the same day.
Auditor reported no modified opinion or material emphasis of matter.

Filed 16:18View Source

13 Apr 20261 filing

OthersFormat of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....

Filed 17:35View Source

30 Mar 20261 filing

Insider Trading / SASTClosure of Trading Window

Closure of Trading Window from 01st April 2026 till 48 hours after the declaration of financial results for the quarter and financial year ended 31st March 2026.

Filed 10:23View Source

25 Mar 20261 filing

Board MeetingOutcome of Board Meeting

Brawn Biotech Ltd - 530207 - Board Meeting Outcome for ANNOUNCEMENT UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS), 2015

Auditor Appointments

Appointed Mr. Viney as Secretarial Auditor for FY 2025-26 effective March 25, 2026
Appointed M/s Sahil Pasricha & Associates as Internal Auditors for FY 2025-26 effective March 25, 2026

Filed 11:58View Source

5 Mar 20261 filing